Detection of Ciprofloxacin-Resistant, β-Lactamase-Producing Neisseria meningitidis Serogroup Y Isolates - United States, 2019-2020
- PMID: 32555137
- PMCID: PMC7302475
- DOI: 10.15585/mmwr.mm6924a2
Detection of Ciprofloxacin-Resistant, β-Lactamase-Producing Neisseria meningitidis Serogroup Y Isolates - United States, 2019-2020
Abstract
Meningococcal disease is a sudden-onset, life-threatening illness caused by the bacterium Neisseria meningitidis. Prompt empiric antibiotic treatment can reduce morbidity and mortality among patients, and antibiotic prophylaxis can prevent secondary disease in close contacts. Historically, N. meningitidis isolates in the United States have largely been susceptible to the antibiotics recommended for treatment and prophylaxis, including penicillin and ciprofloxacin. This report describes detection of penicillin-resistant and ciprofloxacin-resistant N. meningitidis serogroup Y (NmY) isolates in the United States. NmY isolates containing a blaROB-1 β-lactamase enzyme gene conferring resistance to penicillins (1) were recovered from 33 cases reported during 2013-2020. Isolates from 11 of these cases, reported during 2019-2020, harbored a ciprofloxacin resistance-associated mutation in a chromosomal gene (gyrA). Cases were reported from 12 geographically disparate states; a majority of cases (22 of 33, 67%) occurred in Hispanic persons. These cases represent a substantial increase in penicillin-resistant and ciprofloxacin-resistant meningococci in the United States since 2013. Ceftriaxone and cefotaxime, the recommended first-line agents for empiric bacterial meningitis treatment, can continue to be used for treatment, but health care providers should ascertain susceptibility of meningococcal isolates to penicillin before switching to penicillin or ampicillin. Ongoing monitoring for antimicrobial resistance among meningococcal isolates and prophylaxis failures will be important to inform treatment and prophylaxis recommendations.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Figures
Similar articles
-
Acquisition of Ciprofloxacin Resistance Among an Expanding Clade of β-Lactamase-Positive, Serogroup Y Neisseria meningitidis in the United States.Clin Infect Dis. 2021 Oct 5;73(7):1185-1193. doi: 10.1093/cid/ciab358. Clin Infect Dis. 2021. PMID: 33900407 Free PMC article.
-
Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19).PLoS One. 2021 Nov 29;16(11):e0260677. doi: 10.1371/journal.pone.0260677. eCollection 2021. PLoS One. 2021. PMID: 34843604 Free PMC article.
-
Penicillin- and Ciprofloxacin-Resistant Invasive Neisseria meningitidis Isolates from Japan.Microbiol Spectr. 2022 Jun 29;10(3):e0062722. doi: 10.1128/spectrum.00627-22. Epub 2022 Apr 25. Microbiol Spectr. 2022. PMID: 35467371 Free PMC article.
-
Emergence and spread of resistant N. meningitidis implicated in invasive meningococcal diseases during the past decade (2008-2017).J Antibiot (Tokyo). 2019 Mar;72(3):185-188. doi: 10.1038/s41429-018-0125-0. Epub 2018 Nov 27. J Antibiot (Tokyo). 2019. PMID: 30479393 Review.
-
Antibiotics for preventing meningococcal infections.Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004785. doi: 10.1002/14651858.CD004785.pub3. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2011 Aug 10;(8):CD004785. doi: 10.1002/14651858.CD004785.pub4 PMID: 17054214 Updated. Review.
Cited by
-
Statewide Outbreak of Neisseria meningitidis Serogroup Y, Sequence Type 1466 - Virginia, 2022-2024.MMWR Morb Mortal Wkly Rep. 2024 Oct 31;73(43):973-977. doi: 10.15585/mmwr.mm7343a3. MMWR Morb Mortal Wkly Rep. 2024. PMID: 39480707 Free PMC article.
-
Public health trends in neurologically relevant infections: a global perspective.Ther Adv Infect Dis. 2024 Sep 17;11:20499361241274206. doi: 10.1177/20499361241274206. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 39301451 Free PMC article. Review.
-
Selection of Antibiotics as Prophylaxis for Close Contacts of Patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance - United States, 2024.MMWR Morb Mortal Wkly Rep. 2024 Feb 8;73(5):99-103. doi: 10.15585/mmwr.mm7305a2. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38329923 Free PMC article.
-
The Diverse Spectrum of Invasive Meningococcal Disease in Pediatric and Adolescent Patients: Narrative Review of Cases and Case Series.Infect Dis Ther. 2024 Feb;13(2):251-271. doi: 10.1007/s40121-023-00906-x. Epub 2024 Jan 29. Infect Dis Ther. 2024. PMID: 38285269 Free PMC article. Review.
-
Microevolution and Its Impact on Hypervirulence, Antimicrobial Resistance, and Vaccine Escape in Neisseria meningitidis.Microorganisms. 2023 Dec 18;11(12):3005. doi: 10.3390/microorganisms11123005. Microorganisms. 2023. PMID: 38138149 Free PMC article. Review.
References
-
- Meningococcal infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red book: 2018–2021 report of the committee on infectious diseases, 31st edition. Itasca, IL: American Academy of Pediatrics; 2018. https://redbook.solutions.aap.org/chapter.aspx?sectionid=189640131&booki...
-
- Cohn AC, MacNeil JR, Clark TA, et al.; CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(No. RR-2). - PubMed
-
- McNamara LA, Blain A. Meningococcal disease. In: Roush SW, Baldy LM, Hall MAK, eds. Manual for the surveillance of vaccine-preventable diseases. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
